

## **MPAC meeting 14 – 16 September 2016**

### **Declaration of Interests**

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat

Ten members reported relevant interests, which are summarized below.

Of note, several members (Brian Greenwood, Marcel Tanner, Kevin Marsh, Azra Ghani, Laurence Slutsker) have been involved in RTS,S phase 3 trials, for which their interest has been assessed as significant, non-personal and non-specific with regard to the topics and sessions that will be discussed during this MPAC meeting. There will be no decision point related to the RTS,S malaria vaccine and, for this reason, they will be not recused from the information session related to the topic.

All reported relevant interests by MPAC members are summarized below:

#### **Azra GHANI**

Receives an academic grant funding from multiple organisations: the Bill & Melinda Gates Foundation (BMGF), IVCC, Malaria Vaccine Initiative (MVI), Medicines for Malaria Venture (MMV), Medical Research Council (MRC), Wellcome Trust, and the National Institutes of Health (NIH). Currently, Dr Ghani is running a consultancy project for the Global Fund. This interest was assessed to be non-personal, non-specific, and financially significant.\*

#### **Thomas BURKOT**

Received consulting and research support from Intellectual Ventures Labs (IVL) for two projects; one, on the potential role of IVL in mosquito control, which concluded a year ago and the other on the evaluation of a novel diagnostic test developed by IVL in the Salomon Islands, which concluded in March 2016. Since May 2016, he receives a fellowship to help IVL create a vector control programme to support malaria control. This interest was assessed to be non-personal, non-specific, and financially significant.\*

#### **Brian GREENWOOD**

Receives a research grant from PATH for the London School of Hygiene and Tropical Medicines related to the evaluation of the RTS,S vaccines in Ghana, this project ceased this year. This interest was assessed as non-personal, non-specific and financially significant\*.

#### **Rose Gana Fomban LEKE**

Receives research grant from the National Institute of Allergy and Infectious Diseases (NIAID), USA in malaria in pregnancy. In 2013 she chaired the Data Management and Safety Board (DMSB) for Clinical Trial on Azithromycin in pregnant women. This interest was assessed as personal, non-specific, and financially significant\*.

#### **Kevin MARSH**

Chair of the MPAC at WHO and senior adviser for the African Academy of Sciences, he is on the malaria vaccines advisory group for USAID and malaria advisory group at the Bill &

Melinda Gates Foundation (BMGF). Dr Marsh is a principal investigator on the Phase 3 RTS,S study and a collaborator on a Phase 2 malaria vaccine trials. This interest was assessed as non-personal, non-specific, and not financially significant\*.

### **Marcel TANNER**

Director Emeritus and member of the Swiss Tropical and Public Health Institute, which receives research funding from Novartis Institute for Tropical Diseases (NITD), Swiss National Science Foundation (SNF), Wellcome Trust, MVI and the Bill & Melinda Gates Foundation (BMGF) with regard to the RTS,S vaccine. Dr Tanner is member of various steering committees and advisory boards; he has done consulting for NITD and is member of the Scientific Advisory Board in Singapore. This interest was assessed to be non-personal, non-specific, and financially significant.\*

### **Neena VALECHA**

Directs the National Institute of Malaria Research – New Delhi, which receives research grants to undertake the evaluation of pesticide products and trials of drugs/diagnostics of various companies after obtaining approval from the Scientific Advisory Committee and the Ethical committee. From WHOPEs, on large scale (Phase III) evaluation of efficacy, fabric integrity and community acceptability of Permanent 3.0 long lasting insecticide dal nets compared with Permanent 2.0 in India. From Vestergaard Frandsen Ltd., to evaluate the efficacy of PermaNet 3.0 long lasting insecticidal net in areas with variable dethramethirine-resistance malaria vectors in India and from MMW Geneva for Phase IIIB open label trial for safety and efficacy of Euratesim® in India against children with uncomplicated *pf*. This interest was assessed as non-personal, non-specific and not financially significant\*.

### **Jose Gabriel CARRASQUILLA**

Directs ASIESALUD for consultancy and research in epidemiology and public health, where as principal investigator receives a research grant from GSK to assess the impact of the introduction of Pneumo vaccine and Pertussis vaccine (in pregnant women) in South America. This interest was assessed as personal, non-specific and not financially significant.

### **Nicholas WHITE**

Receives salary and research support from the Wellcome Trust. Advice to organizations developing antimalarial drugs is done on a pro bono basis and no fees of consultancies are accepted. This interest was assessed as non-personal, non-specific and significant.

### **Laurence SLUTSKER**

PATH/MVI receives funding from BMGF in support of RTS,S development. This interest was assessed as non-personal, non-specific and significant

---

\*According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a "significant shareholding". Last update: 10<sup>th</sup> March 2016